ライフサイエンスコーパス: sexual dysfunction

1 h medical and public discourse about 'Female Sexual Dysfunction'.

2 mproving symptoms of depression, fatigue, or sexual dysfunction.

3 nderlying the link between LUTS/BPH and male sexual dysfunction.

4 ed for the association between LUTS and male sexual dysfunction.

5 rofiles, and signs of prolactin elevation or sexual dysfunction.

6 f attempted suicide, child abuse, and recent sexual dysfunction.

7 ter cope with their posttreatment urinary or sexual dysfunction.

8 uch as bladder stones, increased the rate of sexual dysfunction.

9 lationships and masculinity, which accompany sexual dysfunction.

10 suggested a causal relation between BPH and sexual dysfunction.

11 nd only small increased risks of fatigue and sexual dysfunction.

12 on with symptoms of depression, fatigue, and sexual dysfunction.

13 ntial roles as therapeutic agents for female sexual dysfunction.

14 evelop appropriate management strategies for sexual dysfunction.

15 mining the pharmacological aspects of female sexual dysfunction.

16 bo in ameliorating antidepressant-associated sexual dysfunction.

17 gs in the evaluation and treatment of female sexual dysfunction.

18 ial groups demonstrate different patterns of sexual dysfunction.

19 the adjuvant setting experienced symptoms of sexual dysfunction.

20 ated complications, including, unexpectedly, sexual dysfunction.

21 d ovarian reserve, reduced sperm quality and sexual dysfunction.

22 ith psychotomimetic effects, weight gain, or sexual dysfunction.

23 in patients with cancer, such as fatigue and sexual dysfunction.

24 ndergoing treatment and were concerned about sexual dysfunction.

25 is a potential therapy in the management of sexual dysfunction.

26 ) tract, often accompanied by depression and sexual dysfunction.

27 bladder syndrome, as well as male and female sexual dysfunction.

28 life, with some patients reporting bowel and sexual dysfunction.

29 mage, and menopausal symptoms in BCSs with a sexual dysfunction.

30 urvivors (BCSs) with a DSM-IV diagnosis of a sexual dysfunction.

31 including hot flashes, vaginal dryness, and sexual dysfunction.

32 al sexual differentiation and any associated sexual dysfunction.

33 ty-of-life impairment, including itching and sexual dysfunction.

34 ention that was implemented to alleviate the sexual dysfunction.

35 en do not receive adequate support to manage sexual dysfunction.

36 e link between metabolic syndrome (MetS) and sexual dysfunction.

37 emerged pointing to a relationship with male sexual dysfunction.

38 n and urinary tract erosion, thigh pain, and sexual dysfunction.

39 tions in testosterone truly account for male sexual dysfunction.

40 ypogonadism and its correlation with QoL and sexual dysfunction.

41 to be associated with increased urinary and sexual dysfunction.

42 e baseline function had similar increases in sexual dysfunction.

43 l in the evaluation and treatment outcome of sexual dysfunction.

44 itted by SRIs but who were also experiencing sexual dysfunction.

45 brief sexual counseling can often alleviate sexual dysfunction.

46 obesity, cancer, cardiovascular disease and sexual dysfunction.

47 g with treatment-related urinary, bowel, and sexual dysfunction.

48 symptom in men with CP/CPPS as it relates to sexual dysfunction.

49 fects older men and is often associated with sexual dysfunction.

50 used to identify factors associated with the sexual dysfunction.

51 1), depression (1.35; 1.32-1.38; p < 0.001), sexual dysfunction (1.27; 1.17-1.38; p < 0.001), and sle

52 heart failure (1.81 [1.21-2.69], CE = weak), sexual dysfunction (2.30 [1.75-3.04], CE = weak), fractu

53 d mean baseline scores were 41.8 to 46.4 for sexual dysfunction, 20.8 to 22.8 for urinary obstruction

54 nificant annual increase in risk of reported sexual dysfunction (5 per 1000 patients; 95% CI, 2-8), e

55 ruritus (39%), poor-quality sleep (63%), and sexual dysfunction (53%).

56 ep disturbance (59.9%; 95% CI, 53.9%-63.9%), sexual dysfunction (59.8%; 95% CI, 50.0%-69.5%), constip

57 problems (7.7 [7.8] vs 7.9 [9.1]; P = .70), sexual dysfunction (68.2 [34.6] vs 65.9 [34.7]; P = .65)

58 Urinary and sexual dysfunctions affecting quality of life were asses

59 Sexual dysfunction after radiotherapy increased less but

60 determined potential confounding factors of sexual dysfunction: age; disease duration; physical disa

61 adotoxic treatments, fertility concerns, and sexual dysfunction (all P < .05).

62 vious unsuccessful attempts to conceive, and sexual dysfunction (all P < .05).

63 tures, myocardial infarction, and markers of sexual dysfunction, although there are few studies for e

64 1% of patients reported severe problems with sexual dysfunction and 11.9% with abdominal pain.

65 opriate screening, information, and support, sexual dysfunction and accompanying distress can be sign

66 r, and somatic symptom disorders, as well as sexual dysfunction and aspects of personality disorders.

67 With increasing age, sexual dysfunction and BPH become more prevalent.

68 consistent finding is a correlation between sexual dysfunction and depression.

69 es, mutations reducing fertility may lead to sexual dysfunction and even the loss of sex.

70 tal and extragenital skin, which can lead to sexual dysfunction and has been associated with vulvar c

71 Previously reported associations between sexual dysfunction and hypertension, diabetes, and depre

72 Treatment-induced symptoms might include sexual dysfunction and impairment of sleep, mood, and qu

73 henotypes in this syndrome, such as obesity, sexual dysfunction and possibly sleep abnormalities.

74 This review explores the links between sexual dysfunction and prostatitis.

75 mpare higher doses of bupropion for treating sexual dysfunction and should include a greater number o

76 ata from individual studies showed that male sexual dysfunction and urinary dysfunction (three studie

77 Greater sexual dysfunction and urinary incontinence occur in the

78 reported on depressive symptoms, fatigue, or sexual dysfunction and were selected for inclusion.

79 bladder irritability, by increasingly severe sexual dysfunction and, in men aged more than 65 years,

80 lus questions about use of interventions for sexual dysfunction) and generic HRQOL (assessed with the

81 sia, headaches, difficulty in concentrating, sexual dysfunction, and digestive disturbances.

82 substantial increase in menopausal symptoms, sexual dysfunction, and diminished quality of life.

83 ween primary treatment, urinary dysfunction, sexual dysfunction, and general health-related quality o

84 effective procedure, with low morbidity, no sexual dysfunction, and good short- and intermediate-ter

85 th adverse birth outcomes, hyperandrogenism, sexual dysfunction, and impaired implantation in humans,

86 apeutic indications, including inflammation, sexual dysfunction, and obesity.

87 studies of combination therapy for LUTS/BPH, sexual dysfunction, and other age-associated comorbiditi

88 er importance on procedure-related bleeding, sexual dysfunction, and perforation.

89 ence, cognitive changes, somatic complaints, sexual dysfunction, and reduced quality of life may be s

90 xercise training, fatigue, bowel/bladder and sexual dysfunction, and sleep disruption.

91 sculine self-esteem and little distress from sexual dysfunction, and were married.

92 The degree of sexual dysfunction appears to be linked with the degree

93 erectile dysfunction, epidemiologic data on sexual dysfunction are relatively scant for both women a

94 Urinary and sexual dysfunctions are recognized complications of rect

95 le cramps, poor-quality sleep, pruritus, and sexual dysfunction, are common and treatable.

96 as chronic diarrhea, dizziness, fatigue, and sexual dysfunction, are due to cholinergic autonomic dys

97 uate discrimination on 4 of the 5 domains of sexual dysfunction (area under the receiver operating ch

98 e increased psychological distress caused by sexual dysfunction (areas of which are unmeasured after

99 east 6 weeks, who were euthymic, and who had sexual dysfunction as determined by a total score greate

100 buspirone and amantadine in the treatment of sexual dysfunction associated with fluoxetine administra

101 other aspects of sexual function in men with sexual dysfunction associated with the use of SRI antide

102 amelioration of, the hyperprolactinemia and sexual dysfunction associated with these drugs.

103 /-) mice demonstrated stereotypic behaviors, sexual dysfunction, bimodal extremes of locomotion, augm

104 Sexual dysfunction, but not other patient-reported funct

105 atients reported greater urinary, bowel, and sexual dysfunction, but similar health status.

106 The risk of sexual dysfunction can be quantified preoperatively usin

107 In men, sexual dysfunction can be related to the hyperestrogenis

108 udy enrolment, with a positive screening for sexual dysfunction causing distress according to the Nat

109 ept pain (coefficient = -11.0%; P = .05) and sexual dysfunction (coefficient = -24.1%; P < .001).

110 yndromes that are reported after HCT include sexual dysfunction, cognitive problems, fatigue, insomni

111 Pelvic organ prolapse, urinary, bowel and sexual dysfunction, collectively called pelvic floor dys

112 mic and thrombotic events, endocrine events, sexual dysfunction, dementia, and depression.

113 The effect of sexual dysfunction deteriorated with age (odds ratio for

114 another paraphilia diagnosis, and 24% for a sexual dysfunction diagnosis.

115 ticipants reported on the negative impact of sexual dysfunction due to end-stage kidney disease (ie,

116 ptors as possible treatments for obesity and sexual dysfunction due to the role of these receptors in

117 Sexual dysfunction during and after cancer treatment is

118 he route of administration, risk of fatigue, sexual dysfunction, dysphagia, shortness of breath and/o

119 en appear slightly more likely to experience sexual dysfunctions, especially later in life.

120 risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue, receipt of opioid analgesic

121 Female sexual dysfunction (FSD) is an important but controversi

122 Female sexual dysfunction (FSD) is common and affects women of

123 Profound sexual dysfunction has been shown to have a significant

124 In women, sexual dysfunction has not been associated with serum te

125 ease associated pelvic pain; infertility and sexual dysfunction have a significant adverse clinical,

126 tion in women with antidepressant-associated sexual dysfunction have been reported, and there is unce

127 ny diagnosis was associated with urinary and sexual dysfunction [hazard ratio (HR) 5.9, 95% confidenc

128 mental disorders), contraception, abortion, sexual dysfunction, hypersexuality, sexual violence, rep

129 ng an integrative treatment model to address sexual dysfunction in a cancer survivorship treatment se

130 LUTS/BPH is an independent risk factor for sexual dysfunction in aging men.

131 luate the hypothesis that fluoxetine-induced sexual dysfunction in female rats derived from disruptio

132 arizes current knowledge about the nature of sexual dysfunction in gynecological cancers, highlightin

133 nesis, testosterone deficiency, and physical sexual dysfunction in male pubertal, adolescent, and you

134 wever, options for managing other domains of sexual dysfunction in men and women remain poor.

135 g muscle cramps, and tadalafil for improving sexual dysfunction in men.

136 aires have lead to a better understanding of sexual dysfunction in men.

137 he current literature on the pathogenesis of sexual dysfunction in patients with cirrhosis and propos

138 rial of a multimodal intervention to address sexual dysfunction in survivors of HSCT at Massachusetts

139 e is a potential target for the treatment of sexual dysfunction in the male.

140 logical stressors also contribute to causing sexual dysfunction in these IBS patients.

141 n men with age-related low testosterone with sexual dysfunction in whom there is no improvement in se

142 is study population, sildenafil treatment of sexual dysfunction in women taking SRIs was associated w

143 rmacological approaches to the management of sexual dysfunction in women.

144 tions of female sexual problems, and 'Female Sexual Dysfunction' in particular, throughout the 20th c

145 Hormonal imbalances may contribute to sexual dysfunction, in particular sexual arousal disorde

146 depending upon their age, have complaints of sexual dysfunction, including decreased libido, vaginal

147 Sexual dysfunction increased in all patients, particular

148 Sexual dysfunction increased steadily over the study per

149 cts of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatme

150 sustained-release bupropion with placebo for sexual dysfunction induced by selective serotonin reupta

151 idimensional Fatigue Inventory), bladder and sexual dysfunction (International Prostate Symptom Score

152 aimed to assess the efficacy of a multimodal sexual dysfunction intervention for improving sexual hea

153 Sexual dysfunction is a common adverse effect of antidep

154 Sexual dysfunction is a common adverse effect of prostat

155 Antidepressant-associated sexual dysfunction is a common adverse effect that frequ

156 Sexual dysfunction is a common clinical symptom in women

157 Sexual dysfunction is a common complication affecting su

158 In summary, sexual dysfunction is a common finding in both men and w

159 d as an important aspect of human wellbeing, sexual dysfunction is a common symptom of mental health

160 Female sexual dysfunction is a common, multifactorial medical c

161 Female sexual dysfunction is a significant problem that affects

162 Female sexual dysfunction is also now gaining some attention, w

163 The results indicate that sexual dysfunction is an important public health concern

164 Sexual dysfunction is common among women with schizophre

165 Sexual dysfunction is common and most men are not offere

166 tients awaiting kidney transplantation (KT), sexual dysfunction is common owing to end-stage kidney d

167 Moreover, sexual dysfunction is highly associated with negative ex

168 Research into different domains of sexual dysfunction is likely to lead to additional thera

169 Experience of sexual dysfunction is more likely among women and men wi

170 Sexual dysfunction is more prevalent for women (43%) tha

171 l risks of depressive symptoms, fatigue, and sexual dysfunction is not supported by data from clinica

172 Sexual dysfunction is often underdiagnosed in the cohort

173 Sexual dysfunction is one of the most common and distres

174 hom an associated non-neurological cause for sexual dysfunction is suspected).

175 n treatment of BPH (or watchful waiting) and sexual dysfunction is usually coincidental, unless sympt

176 development of behavioral problems, such as sexual dysfunction, later in life.

177 ociated with neuropsychological deficits and sexual dysfunction, leading to worse quality of life (Qo

178 Sexual dysfunction like ejaculation discomfort is descri

179 l sexual maturation, idiopathic infertility, sexual dysfunction, low serum testosterone concentration

180 e frequently interrupts sexual function, and sexual dysfunction may signal serious endocrine disease.

181 , 30-day mortality, bladder dysfunction, and sexual dysfunction, none showed a statistically signific

182 Vasomotor symptoms and sexual dysfunction occur frequently in women who have an

183 Sexual dysfunction occurred in 18% of patients and was p

184 Sexual dysfunction occurred more frequently in women who

185 r comorbidities, and 17 to avoid the risk of sexual dysfunction or infertility.

186 ve disorders, they were widowhood (RR=5.59), sexual dysfunction (OR=2.71), three (OR=1.99) or four-fi

187 s, digoxin and thiazide diuretics may worsen sexual dysfunction owing to medication side effects.

188 ad greater psychopathology (most ps < 0.05), sexual dysfunction (p < 0.03) and worse QoL (p < 0.001)

189 Owing to the link between LUTS/BPH and male sexual dysfunction, patients presenting with one of thes

190 ses considerable patient morbidity including sexual dysfunction, poor mood and physical capacity, cha

191 rols, each therapy group reported bothersome sexual dysfunction; radical prostatectomy was associated

192 ndomized studies exist to guide treatment of sexual dysfunction related to MetS; rather, most studies

193 Thus, despite some recovery, sexual dysfunction remained a major problem for men and

194 ng innervation, are reflected in the urinary/sexual dysfunction's in aged animals.

195 Compared with active surveillance, mean sexual dysfunction scores worsened by 3 months for patie

196 Sexual dysfunction (SD) is a common non-motor symptom in

197 l as changes in pathologic conditions, i.e., sexual dysfunction, sexual deviation, or sexual risk-tak

198 s, chest pain and abdominal pain) or involve sexual dysfunction, sleep disorders and fatigue.

199 Sexual dysfunction, sleep disturbance, constipation, red

200 Chronic pain is often associated with sexual dysfunction, suggesting that pain can reduce libi

201 Men who never smoked reported less sexual dysfunction than did those who either had quit or

202 lantation, women reported significantly more sexual dysfunction than men.

203 terectomy was associated with lower rates of sexual dysfunction than radical hysterectomy, with a low

204 ded about key risk factors and predictors of sexual dysfunction that can be used to guide appropriate

205 adverse effects such as urinary symptoms and sexual dysfunction that can negatively affect quality of

206 For sexual dysfunction, the models in the two samples explai

207 thematical model for quantifying the risk of sexual dysfunction through time for this group of patien

208 The instrument contains 4 domains-sexual dysfunction, urinary obstruction and irritation,

209 Treatment of bowel, bladder and sexual dysfunction utilizing a variety of modalities has

210 tion after 12 months, but the time course of sexual dysfunction varied by treatment and, for bowel fu

211 ntributions of chemotherapy and tamoxifen to sexual dysfunction warrant prospective study.

212 Structurally, sexual dysfunction was associated with a substantial los

213 Transient sexual dysfunction was noted in 3 of 14 patients, but no

214 The odd in sexual dysfunction was significant for PIGD.

215 ith adjuvant endocrine therapy (hot flashes, sexual dysfunction, weight gain, musculoskeletal symptom

216 Urinary, bowel, and sexual dysfunction were assessed with symptom indexes; h

217 Bowel and sexual dysfunction were associated with poorer sexual in

218 Urinary incontinence and erectile and sexual dysfunction were each greater with surgery than w

219 Vaginal atrophy, sexual interest, and sexual dysfunction were improved.

220 primary treatment, urinary dysfunction, and sexual dysfunction were independently associated with ge

221 OFS results in more menopausal symptoms and sexual dysfunction, which contributes to inferior self-r

222 n men with age-related low testosterone with sexual dysfunction who want to improve sexual function (

223 dence of an association between LUTS/BPH and sexual dysfunction will be reviewed, as well as the effe

224 logists are benign prostatic hyperplasia and sexual dysfunction, with an increasing number of patient